Cotadutide

Description

Cotadutide: Dual GLP-1 & Glucagon Receptor Agonist for Obesity, Type 2 Diabetes & NASH – Once-Daily Peptide Therapy

Cotadutide (formerly MEDI0382) is a potent, balanced dual agonist of the GLP-1 (glucagon-like peptide-1) and glucagon receptors developed by AstraZeneca. Engineered as a synthetic peptide with an extended half-life, cotadutide offers once-daily subcutaneous dosing and delivers superior glycemic control, significant body-weight reduction, and promising liver-fat reduction – making it one of the most exciting investigational therapies for obesity, type 2 diabetes mellitus (T2DM), and non-alcoholic steatohepatitis (NASH).

Key Benefits of Cotadutide

• Powerful weight loss: Phase 2b trials showed up to −7.2 % body weight reduction at 54 weeks (vs. −2.6 % with liraglutide and −1.3 % placebo).
• Robust HbA1c reduction: Up to −1.6 % lowering in patients with T2DM, outperforming many single GLP-1 agonists.
• Significant liver fat reduction: Up to −39 % relative reduction in liver fat content in NASH patients (MRI-PDFF), with histological improvements in fibrosis and inflammation.
• Cardiometabolic improvements: Reduced fasting plasma glucose, improved insulin sensitivity, lowered triglycerides, and favorable effects on blood pressure.
• Convenient once-daily dosing thanks to built-in half-life extension technology (no weekly injection required like semaglutide or tirzepatide in some regimens).

Why Cotadutide Stands Out Among GLP-1/Glucagon Agonists

Unlike pure GLP-1 agonists (semaglutide, liraglutide, dulaglutide) or GLP-1/GIP co-agonists (tirzepatide), cotadutide uniquely activates the glucagon receptor. This additional mechanism drives greater energy expenditure, enhanced lipid metabolism, and superior hepatic fat clearance – especially valuable in patients with obesity-driven NASH and metabolic dysfunction-associated steatohepatitis (MASH).

Clinical Evidence (Published Phase 2 Data)

• 834 patients with T2DM (NCT03444584): cotadutide 300 µg demonstrated superior weight loss and glycemic control vs. placebo and liraglutide.
• 270 patients with NASH (NCT04019561, “AURORA”): dose-dependent reductions in liver fat, ALT, AST, and Pro-C3 (fibrosis marker), meeting both primary and multiple secondary endpoints.

Ideal Candidates for Cotadutide Therapy

• Adults with BMI ≥30 kg/m² (obesity) or ≥27 kg/m² with weight-related comorbidities
• Patients with type 2 diabetes inadequately controlled on metformin or other oral agents
• Individuals with biopsy-confirmed or imaging-diagnosed NASH/MASH seeking non-surgical options

Current Status (December 2025)

Cotadutide is currently in late-stage clinical development. AstraZeneca is advancing Phase 3 programs for obesity and NASH/MASH, with anticipated regulatory submissions in the coming years.

Purchasing Cotadutide online in Adelaide Australia. Discover the next generation of dual-incretin therapy. Cotadutide combines best-in-class weight loss, glycemic efficacy, and liver-directed benefits in a single daily injection – positioning it as a potential game-changer alongside semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and upcoming multi-receptor agonists.